Reducing the risk of breast cancer

New England Journal of Medicine

Volumn 343, Issue 3, 2000, Pages 191-198

  Chlebowski, Rowan T ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENRETINIDE; RALOXIFENE; TAMOXIFEN;

ADULT; AGED; ALCOHOL ABSTINENCE; BREAST CANCER; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG USE; EXERCISE; FEMALE; HUMAN; LIFESTYLE; LOW FAT DIET; MASTECTOMY; OVARIECTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; WEIGHT REDUCTION;

ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; ENVIRONMENT; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; LIFE STYLE; MASTECTOMY; OVARIECTOMY; RALOXIFENE; RISK FACTORS; TAMOXIFEN;

EID: 0034691671     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200007203430307     Document Type: Review

References (91)

1. Henderson BE, Ross R, Bernstein L. Estrogen as a cause of human canter: the Richard and Hilda Rosenthal Foundation Award lecture. Cancer Res 1988;48:246-53.
2. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk of breast cancer. Ann Intern Med 1999;130:270-7.
3. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-91.
4. Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Canecr Inst 1998;90:814-23.
5. Chlebowski RT, McTiernan A. Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer. J Clin Oncol 1999;17:130-42.
6. Lacassagne A. Hormonal pathogenesis of adenocarcinoma of the breast. Am J Cancer 1936;27:217-28.
7. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Mcd 1998;339:1609-18.
8. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993-2000.
9. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
10. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320:479-84.
11. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet 1985;2:282.
12. Powles TJ, Hardy JR, Ashley SE, et al. Chemoprevention of breast cancer. Breast Cancer Res Treat 1989;14:23-31.
13. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-I Study. J Natl Cancer Inst 1998;90:1371-88.
14. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
15. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999;281:2189-97. [Erratum, JAMA 1999;282:2124.]
16. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
17. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Lancet 1998;352:93-7.
18. Veronesi U, De Palo G, Marubini E, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999;91:1847-56.
19. Gray R. Conflicting results from tamoxifen studies: a simple explanation. Breast 1999;8:225. abstract.
20. Pritchard KI. Is tamoxifen effective in prevention of breast cancer? Lancet 1998;352:80-1.
21. Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG. American Society of Clinical Oncology technology assessment of breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 1999;17:1939-55.
22. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;9:1829-46. [Erratum, J Natl Cancer Inst 2000;92:275.]
23. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999;17:2659-69.
24. Bernstein L, Deapen D, Cerhan JR, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999;91:1654-62.
25. Shushan A, Peretz T, Uziely B, Lewin A, Mor-Yosef S. Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Am J Obstet Gynecol 1996;174:141-4.
26. Suh-Burgmann EJ, Goodman A. Surveillance for endometrial cancer in women receiving tamoxifen. Ann Intern Med 1999;131:127-35.
27. Love RR, Mazess RB, Tormey DC, Barden HS, Newcomb PA, Jordan VC. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 1988;12:297 302.
28. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14:78-84.
29. Bilimoria MM, Jordan VC, Morrow M. Additional benefits of tamoxifen for postmenopausal patients. In: Jordan VC, ed. Tamoxifen: a guide for clinicians and patients. Huntington, N.Y.: PRR, 1996:75-89.
30. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
31. Nayfield SG, Gorin MB. Tamoxifen-associated eye disease: a review. J Clin Oncol 1996;14:1018-26.
32. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev 1999;20:279-307.
33. Van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998;90: 210-8.
34. Taylor AL, Adams-Campbell LL, Wright JT Jr. Risk/benefit assessment of tamoxifen to prevent breast cancer - still a work in progress? J Natl Cancer Inst 1999;91:1792-3.
35. McCaskill-Stevens W, Bryant J, Costantino J, Wickerham DL, Vogel V, Wolmark N. Incidence of contralateral breast cancer (CBC), endometrial cancer (EC) and thromboembolic events (TE) in African American (AA) women receiving tamoxifen for treatment of primary breast cancer. Prog Proc Am Soc Clin Oncol 2000;19:70a. abstract.
36. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7.
37. Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 1999;130:431-9.
38. Jordan VC, Morrow M. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 1999;20:253-78.
39. Gradishar WJ, Glusman JE, Vogel CL, et al. Raloxifene HCL, a new endocrine agent, is active in estrogen receptor positive (ER+) metastatic breast cancer. Breast Cancer Res Treat 1997;46:53. abstract.
40. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. JAMA 1996;276:1404-8.
41. Jordan VC, Glusman JE, Eckert S, et al. Raloxifene reduces incident primary breast cancers: integrated data from multicenter, double blind, placebo-controlled, randomized trials in postmenopausal women. Breast Cancer Res Treat 1998;50:227. abstract.
42. Jordan VC, Morrow M. Raloxifene as a multifunctional medicine? Current trials will show whether it is effective in both osteoporosis and breast cancer. BMJ 1999;319:331-2.
43. Fugere P, Scheele WH, Shah A, Strack TR, Glant MD, Jolly E. Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 2000;182:568-74.
44. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-51.
45. Hughes KS, Papa MZ, Whitney T, McLellan R. Prophylactic mastectomy and inherited predisposition to breast cancer. Cancer 1999;86:Suppl: 2502-16.
46. Eisen A, Rebbeck TR, Wood WC, Weber BL. Prophylactic surgery in women with hereditary predisposition to breast and ovarian cancer. J Clin Oncol 2000;18:1980-95.
47. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84.
48. Hartmann LC, Schaid D, Sellers T, et al. Bilateral prophylactic mastectomy (PM) in BRCA1/2 mutation carriers. Proc Am Assoc Cancer Res 2000;41:222. abstract.
49. Wennberg DE, Birkmeyer JD, Lucas FL. Pounds of prevention for ounces of cure: surgery as a preventive strategy. Lancet 1999;353:Suppl 1: SI-9-SI-11.
50. Eisen A, Weber BL. Prophylactic mastectomy - the price of fear. N Engl J Med 1999;340:137-8.
51. Khalkhali I, Diggles LE, Taillefer R, Vandestreck PR, Peller PJ, Abdel-Nabi HH. Procedure guidelines for breast scintigraphy. J Nucl Med 1999; 40:1233-5.
52. Frost MH, Woods J, Slezak J, et al. Bilateral prophylactic mastectomy: long-term satisfaction, psychological and social function. Prog Proc Am Soc Clin Oncol 1999;18:2218. abstract.
53. Borgen PI, Hill AD, Tran KN, et al. Patient regrets after bilateral prophylactic mastectomy. Ann Surg Oncol 1998;5:603-6.
54. Schairer C, Persson I, Falkeborn M, Naessen T, Troisi R, Brinton LA. Breast cancer risk associated with gynecologic surgery and indications for such surgery. Int J Cancer 1997;70:150-4.
55. Meijer WJ, van Lindert ACM. Prophylactic oophorectomy. Eur J Obstet Gynecol Reprod Biol 1992;47:59-65.
56. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996;348: 1189-96.
57. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999;91:1475-9.
58. Struewing JP, Watson P, Easton DF, Ponder BAJ, Lynch HT, Tucher MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. In: Hereditary breast, ovarian, and colon cancer. Journal of the National Cancer Institute monographs. No. 17. Washington, D.C.: Government Printing Office, 1995:33-5. (NIH publication no. 94-03837.)
59. Spicer DV, Ursin G, Parisky YR, et al. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 1994;86:431-6.
60. Boyd NF, Lockwood G, Martin L, et al. Mammographic densities and risk of breast cancer among subjects with a family history of this disease. J Natl Cancer Inst 1999;91:1404-8.
61. Rutquist LE. Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: a randomized trial by the Cancer Research Campaign (CRC) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, the South-East Sweden Breast Cancer Group and the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (GIVIO). Prog Proc Am Soc Clin Oncol 1999;18:151. abstract.
62. Boccardo F, Blarney RW, Klijn JGM, Tominaga T, Duchateau L, Sylvester R. LHRH-agonist (LHRH-A) + tamoxifen (TAM) versus LHRH-A alone in premenopausal women with advanced breast cancer: results of a meta-analysis of four trials. Prog Proc Am Soc Clin Oncol 1999;18:416. abstract.
63. Conley B, O'Shaughnessy J, Prindiville S, et al. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J Clin Oncol 2000;18:275-83.
64. Labrie F, Labrie C, Belanger A, et al. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Mol Biol 1999;69:51-84.
65. Fabian CJ, Kimler BF, Anderson J, et al. Phase I biomarker and toxicity evaluation of LY353381 (a 3rd generation selective estrogen receptor modulator, SERM) in breast cancer. Prog Proc Am Soc Clin Oncol 2000; 19:290. abstract.
66. Santern RJ, Yue W, Naftolin F, Moi G, Bernstein L. The potential of aromatase inhibitors in breast cancer prevention. Endocr Relat Cancer 1999;6:235-42.
67. Wu AH, Pike MC, Stram DO. Meta-analysis: dietary fat intake, serum estrogen levels, and the risk of breast cancer. J Natl Cancer Inst 1999;91: 529-34.
68. Wynder EL, Cohen LA, Muscat JE, Winters B, Dwyer JT, Blackburn G. Breast cancer: weighing the evidence for a promoting role of dietary fat. J Natl Cancer Inst 1997;89:766-75.
69. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999;341:427-34.
70. Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Hennekens CH, Speizer FE. Moderate alcohol consumption and the risk of breast cancer. N Engl J Med 1987;316:1174-80.
71. Thune I, Brenn T, Lund E, Gaard M. Physical activity and the risk of breast cancer. N Engl J Med 1997;336:1269-75.
72. Hunter DJ, Spiegelman D, Adami HO, et al. Cohort studies of fat intake and the risk of breast cancer - a pooled analysis. N Engl J Med 1996; 334:356-61.
73. Holmes MD, Stampfer MJ, Colditz GA, Rosner B, Hunter DJ, Willett WC. Dietary factors and the survival of women with breast carcinoma. Cancer 1999;86:826-35. [Erratum, Cancer 1999;86:2707-8.]
74. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61-109.
75. Chlebowski RT, Blackburn GL, Buzzard IM, et al. Adherence to a dietary fat intake reduction program in postmenopausal women receiving therapy for early breast cancer: the Women's Intervention Nutrition Study. J Clin Oncol 1993;11:2072-80.
76. Pierce JP, Faerber S, Wright FA, et al. Feasibility of a randomized trial of a high-vegetable diet to prevent breast cancer recurrence. Nutr Cancer 1997;28:282-8.
77. Rose DP, Chlebowski RT, Connolly JM, Jones LA, Wynder EL. Effects of tamoxifen adjuvant therapy and a low-fat diet on serum binding proteins and estradiol bioavailability in postmenopausal breast cancer pa tients. Cancer Res 1992;52:5386-90.
78. Prentice R, Thompson D, Clifford C, Gorbach S, Goldin B, Byar D. Dietary fat reduction and plasma estradiol concentration in healthy postmenopausal women. J Natl Cancer Inst 1990;82:129-34.
79. Boyd NF, Greenberg C, Lockwood G, et al. Effects at two years of a low-fat, high-carbohydrate diet on radiologie features of the breast: results from a randomized trial. J Natl Cancer Inst 1997;89:488-96.
80. Barrett-Connor E. A pill for all by the year 2000? Prev Med 1999;28: 600-7.
81. Ingram D, Sanders K, Kolybaba M, Lopez D. Case-control study of phyto-estrogens and breast cancer. Lancet 1997;350:990-4.
82. Wade C, Kronenberg F, Kelly A, Murphy PA. Hormone-modulating herbs: implications for women's health. J Am Med Womens Assoc 1999; 54:181-3.
83. Laden F, Hunter DJ. Environmental risk factors and female breast cancer. Annu Rev Public Health 1998;19:101-23.
84. Brainard GC, Kavet R, Kheifets LI. The relationship between electromagnetic field and light exposures to melatonin and breast cancer risk: a review of the relevant literature. J Pineal Res 1999;26:65-100.
85. Pritchard KI. Chemoprevention of breast cancer. Alexandria, Va.: ASCO Educational Book, Fall 1999:202-7.
86. Armstrong K, Eisen A, Weber B. Assessing the risk of breast cancer. N Engl J Med 2000;342:564-71.
87. Ellis MJ, Hayes DF. Refining breast cancer risk assessment with molecular markers: the next step? J Natl Cancer Inst 1999;91:2067-8.
88. Bunker JP, Houghton J, Baum M. Putting the risk of breast cancer in perspective. BMJ 1998;317:1307-9.
89. O'Connor AM, Fiset V, DeGrasse C, et al. Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. In: Cancer risk communication: what we know and what we need to learn. Journal of the National Cancer Institute monographs. No. 25. Washington, D.C.: Government Printing Office, 1999:67-80.
90. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis -effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997; 336:1465-71. [Erratum, N Engl J Med 1997;337:434.]
91. Grann VR, Jacobson JS, Whang W, et al. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis. Cancer J Sci Am 2000;6:13-20.